Immunotherapy: Programming T cells in situ
Nature Reviews Cancer 17, 372 (2017).
doi:10.1038/nrc.2017.38
Author: Sarah Seton-Rogers
Adoptive T cell therapy with patient-derived cells engineered ex vivo to express chimeric antigen receptors (CARs) is a promising therapeutic strategy in cancer, but producing these cells for a large number of patients is both technically challenging and cost prohibitive. Smith et al.
Source: Nature Reviews Cancer - Category: Cancer & Oncology Authors: Sarah Seton-Rogers Tags: Research Highlight Source Type: research